Years

Conference Details

Presenters

Speakers

Organizing Committee

Sponsors

Bayhelix China Healthcare Awards

Monday, November 13, 2017
  • Draft Agenda - Subject to Change

6:00 PM to 8:00 PM

  • Welcome Reception
    Grand Hyatt Shanghai, 2nd floor

    Hosted by Alliance Bernstein, BioCentury and BayHelix

Tuesday, November 14, 2017
  • THEME: SCIENCE, INNOVATION & ENTREPRENEURSHIP IN CHINA

8:00 AM to 9:00 AM

  • Registration And Breakfast Networking

    Sponsored by HEDA

9:00 AM to 9:10 AM

  • Welcoming Remarks
    • David Flores, President & CEO, BioCentury Inc.
    • Kewen JIN, M.D., Chairman, BayHelix & Managing Partner, Serica Capital

9:10 AM to 10:00 AM

  • Next Generation Genomics: Is China Setting the Agenda?

    As the genomics revolution gathers steam, the underlying technologies are falling along two axes: Next Generation Sequencing and PCR-based methods. How is China influencing this landscape, and how can it globalize its impact?

    • Victor Shi, Ph.D., Founding President, Asia Pacific, Qiagen & General Partner, Serica Capital (Session Chair & Moderator)
    • Jeff Cheng, Ph.D., CSO, Novogene Corp.
    • Mao MAO, Ph.D., CSO, BGI Genomics Co. Ltd.
    • Steve Sun, Ph.D., Co-Founder & Executive Chairman, Genewiz Inc.
    • Bob Wang, VP & General Manager, Greater China, Agena Bioscience Inc.
    • Ruilin ZHAO, Ph.D., VP & General Manager (Greater China), Illumina Inc.

10:00 AM to 10:30 AM

  • Morning Networking Break

    Sponsored by HEDA

10:30 AM to 11:20 AM

  • Omics To Biomarkers: Can China Lead?

    The wealth of data emerging from large-scale “omics” projects offers a host of new targets for drug development. Will the government’s Precision Medicine Initiative and other initiatives enable China to be a global player in finding the targets and networks that yield predictive biomarkers?

    • Hongye SUN, Ph.D., Chief Technology Officer, WuXi NextCode (Session Chair & Moderator)
    • Yanan CAO, M.D., Professor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    • Jason Jin, Ph.D., Co-Founder & CEO, Cloud Health Genomics Ltd.
    • Leming SHI, Ph.D., Professor & Director, Center for Pharmacogenomics, School of Life Sciences & Shanghai Cancer Center, Fudan University
    • Jennifer Yang, Ph.D., Senior Director, Janssen China R&D, Johnson & Johnson

11:20 AM to 12:10 PM

  • Will China be a Disruptive Force in Diagnostics?

    Chinese companies and investors are showing much more commitment to diagnostics development than their Western counterparts. Given the country’s demographics and disease burden, can China translate this urgency into global leadership in detecting and preventing disease?

    • Simone Fishburn, Ph.D., Editor, BioCentury Innovations (Session Chair & Moderator)
    • Nisa Leung, Managing Partner, Qiming Ventures
    • Shihui YU, M.D., Ph.D., CSO & Chief Scientist, KingMed Diagnostics (Guangzhou KingMed Center for Clinical Laboratory Co. Ltd.)
    • Nick Zhang, Ph.D., Chairman & CEO, Qiagen Suzhou Translational Medicine Co. Ltd.
    • Daixing ZHOU, Ph.D., Co-Founder & CEO, Berry Genomics Co. Ltd.
    • YeQing ZHU, Co-Founder & CEO, New Horizon Health Technology Co. Ltd.

12:10 PM to 1:10 PM

  • Boxed lunch and Networking

1:10 PM to 2:25 PM

  • Artificial Intelligence: Is China Moving Faster in Healthcare AI?

    Artificial intelligence promises to influence almost every aspect of healthcare, and on some fronts may be moving faster in China than anywhere else. Where can China demonstrate the path forward for AI-driven approaches throughout the healthcare value chain?

    • Laura Nelson Carney, Ph.D., Senior Research Analyst, Sanford Bernstein (Session Chair & Moderator)
    • Serafim Batzoglou, Ph.D., VP, Applied & Computational Biology, Illumina Inc.
    • Tom Chittenden, Ph.D., Founding Director, Advanced AI Research Laboratory, WuXi NextCode Genomics Inc.  
    • Andrea de Souza, Global Business Development Lead, Healthcare, NVIDIA Corp.
    • Stanley Li, M.D., Founder, DXY   
    • Yingrui LI, Ph.D., Co-Founder & Chief Scientist, iCarbonX
    • Alex Zhavoronkov, Ph.D., Co-Founder & CEO, Insilico Medicine Inc.

2:25 PM to 3:15 PM

  • Can China Create a Global Platform Against Infectious Diseases?

    China confronts special challenges – and huge opportunities -- in protecting its people from infectious diseases and the scourge of antimicrobial resistance. How can China’s players in public health, research and drug development create a domestic platform that ultimately will provide global solutions?

    • Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair & Moderator)
    • Mark Engel, Chairman & CEO, PhageLux Inc.
    • Zhenkun MA, Ph.D., Founder & CEO, TenNor Therapeutics Ltd.
    • Zhengyu YUAN, Ph.D., Founder, President & CEO, MicuRx Pharmaceuticals Inc.
    • Jim Wu, Ph.D., Founder & CEO, Ark Biosciences Inc.

3:15 PM to 3:45 PM

  • Afternoon Networking Break

3:45 PM to 4:45 PM

  • Can China Transition from Me Too to Me First?

    While many of China's first wave of biotech startups focused on "me too" or "me better" products, a next generation of companies is shifting towards global innovation. How long will it take for China to build a critical mass of first-in-class startups? What are some key factors for success?  

    • Meng JIANG, Managing Director, C-Bridge Capital Partners (Session Co-Chair & Moderator)
    • Jimmy Wei, Ph.D., Managing Partner, I-Bridge Capital (Session Co-Chair & Moderator) 
    • Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund
    • John Oyler, Chairman, Founder & CEO, BeiGene Ltd.
    • Lei XIAO, Ph.D., Chairman & CSO, Innovative Cellular Therapeutics Co. Ltd.
    • Ting XU, Ph.D., Chairman & CEO, Alphamab Co. Ltd.
    • Jingwu ZANG, M.D., Ph.D., Founder & CEO, I-Mab Biopharma

4:45 PM to 5:45 PM

  • International Perspectives: Voices From Abroad

    In the Summit's capstone rapporteur session, biotech leaders from the U.S. and Europe reflect on what they have learned about China's prospects for leadership in science, innovation and entrepreneurship 

    • Karen Bernstein, Ph.D., Chairman and Co-Founder, BioCentury Inc. (Session Chair & Moderator)
    • Sean Cao, Ph.D., President, Everest Medicines, and Managing Director, C-Bridge Capital
    • Joseph Damond, EVP, International Affairs, BIO (Biotechnology Innovation Organization)
    • Jie Liu D’Elia, Ph.D., Executive Director, Business Development Transactions, Bristol-Myers Squibb Co.
    • Matthias Evers, Ph.D., Senior Partner & Global Leader, R&D Practice, McKinsey & Co.
    • Sanjeev Redkar, Ph.D., President & CEO, CBT Pharmaceuticals Inc.

5:45 PM to 8:30 PM

  • Science, Innovation & Entrepreneurship Gala Reception and Networking Dinner

    Hosted by C-Bridge Capital Partners, I-Bridge Capital and BioCentury

Wednesday, November 15, 2017
  • Theme: Managing for the Future in China

8:00 AM to 8:50 AM

  • Registration & Breakfast Networking

    Sponsored by IQVIA

8:50 AM to 9:00 AM

  • Welcoming Remarks
    • Joshua Berlin, Executive Director, New Ventures, BioCentury Inc.

9:00 AM to 10:00 AM

  • Building The Bridge To Innovation: Where Are We Now?

    Insights Partner McKinsey & Co. analyzes the key findings from its 2017 China Healthcare Summit Report, its 4th exclusive report prepared for Summit delegates.

    • Gaobo ZHOU, Partner & Co-Leader, China Healthcare Practice, McKinsey & Co.

10:00 AM to 10:50 AM

  • Joining the Global Club: Is ICH a Game Changer for Innovators in China?

    China’s admission to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has been cheered by biopharma innovators and investors. But what strategies are needed to turn the promise of global standards into the reality of global innovation?

    • Tong GUO, Ph.D., VP & Head, Business Development, Greater China, IQVIA (Session Chair & Moderator)
    • Barbara Esch, Ph.D., Head of Marketing & Business Intelligence, Boehringer Ingelheim GmbH
    • Emil Fu, Ph.D., VP, International Integration, Fountain Medical Development Ltd.
    • Joan Shen, M.D., Ph.D., Head of R&D, I-Mab Biopharma
    • Lin Wang, M.D., VP, Head of Development Center for Asia, Takeda Pharmaceuticals Co. Ltd.
    • Xiaobing WU, Ph.D., Country Manager & Regional President, Greater China Region, Pfizer Inc. and Vice Chairman, RDPAC (R&D-based Pharmaceutical Association Committee)

10:50 AM to 11:20 AM

  • Morning Networking Break

    Sponsored by IQVIA

11:20 AM to 12:20 PM

  • China's Cross-Border Pioneers: Have China's Policy Reforms Transformed the Landscape?

    As China draws closer to international standards, what new strategies are required for China and Western innovators to take advantage of cross-border opportunities for product development, partnership and investment?

    • Tina Tianning Yu, Ph.D., Managing Partner, YuanMing Capital (Session Chair & Moderator)
    • Friedhelm Blobel, Ph.D., CEO, SciClone Pharmaceuticals Inc. 
    • Ji LI, Ph.D., EVP & Global Head of Business Development, BeiGene Ltd.
    • Judith Li, Partner, Lilly Asia Ventures
    • Ryan Liu, VP & CFO, Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. and President, Luoxin Biotechnology (Shanghai) Co. Ltd.
    • James Xue, Ph.D., Founder, Chairman & CEO, CANbridge Life Sciences Ltd.
    • Dajun YANG, M.D., Ph.D., Co-Founder, Chairman & CEO, Ascentage Pharma Group Corp. Ltd. 

12:20 PM to 1:50 PM

  • 8th Annual BayHelix Awards Lunch

    BayHelix again celebrates outstanding individuals and companies for their achievements and contributions to China’s healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

    • Kewen Jin, M.D., Chairman, BayHelix, & Managing Partner, Serica Capital
    • Jimmy Zhang, Ph.D., MBA, Managing Director, Cross-Border Investment, CL Investment Group

1:50 PM to 2:40 PM

  • Capital Markets Strategies: Strategies for East and West

    Has China's evolution created new capital market opportunities at home and abroad? And what are the new dynamics for companies seeking to list on US, HK and China A shares exchanges?

    • Kevin Yi-Jing Xie, Managing Director & Head of Healthcare and Life Sciences, China Renaissance Group (Session Co-Chair & Moderator)
    • Debra Yu, M.D., Managing Director, Head of Cross-Border Healthcare Investment Banking, China Renaissance Securities (Session Co-Chair &  Moderator)
    • Yiqing CHEN, VP & CFO, BGI Genomics Co. Ltd.
    • Chenliang LI, Partner, JunHe LLP 
    • Peter Wirth, Director, Zai Lab Ltd.
    • Benjamin Li, Ph.D., CEO, Lee's Pharmaceutical Holdings Ltd.

2:40 PM to 3:10 PM

  • Afternoon Networking Break

3:10 PM to 4:10 PM

  • Heads of Research Roundtable: How is the Pace of Change Affecting the Front Lines of Innovation?

    In the China Healthcare Summit's second annual research roundtable, R&D leaders in China describe how they are pursuing opportunities and managing challenges they face in embracing innovation and in leading scientific teams in a rapidly changing industry.

    • Steve Yang, Ph.D., EVP, Chief Business Offer & Chief Strategy Officer, WuXi Apptec (Session Chair & Moderator)
    • Baiyong LI, Ph.D., Co-Founder, VP & CSO, Akeso Biopharma Inc.
    • Weiguo SU, Ph.D., Executive Director & CSO, Chi-Med (Hutchison China MediTech Ltd.)
    • Lianshan ZHANG, Ph.D., SVP and President, Global R&D, Jiangsu Hengrui Medicine Co.
    • Zhenping ZHU, M.D., Ph.D., President of R&D and CSO, 3SBio Inc

4:10 PM to 5:30 PM

  • View From The Top: Pharma GM Perspective

    With renewed optimism fueled by China latest regulatory reforms and greater emphasis on successfully launching new products, GMs from leading biopharma MNCs discuss how they are managing for growth in China and building their organizations for continued success.

    • Martin Dewhurst, Senior Partner & Global Leader, Pharmaceuticals and Medical Products Practice, McKinsey & Co. (Session Chair & Moderator)
    • Joseph Romanelli, President, MSD China
    • Thomas Willemsen, Chairman, GSK China Investment Co. Ltd.
    • Xiaobing WU, Ph.D., Country Manager & Regional President, Greater China Region, Pfizer Inc.
    • Ingrid Zhang, Country Pharmaceutical Organization Head, Novartis Pharmaceuticals (China)
    • Wenjie ZHANG, General Manager, China, Amgen Inc.
    • Shirley Zhao, VP & China Country President, Allergan plc

5:30 PM

  • Closing Remarks & Adjourn